

KURZPROTOKOLL **Cassiope**

| | |
|--|--|
| Öffentlicher Titel | Nicht-interventionelle Studie zu Cabozantinib bei fortgeschrittenem Nierenzellkarzinom |
| Wissenschaftl. Titel | Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy |
| Kurztitel | Cassiope |
| Studienart | multizentrisch, Anwendungsbeobachtung, prospektiv, offen/unverblindet, einarmig, Pharma-Studie |
| Studienphase | nicht zutreffend |
| Erkrankung | Niere/Harnwege: Nierenzellkrebs: Zweitlinie oder höher |
| Einschlusskriterien | <ul style="list-style-type: none">- Age \geq18 years old- Has a diagnosis of advanced RCC- Has received at least one prior VEGF-targeted therapy- For whom the treating physician has decided to start treatment with cabozantinib tablets prior to inclusion- No previous exposure to cabozantinib prior to inclusion- Not concurrently involved in an interventional study- Consents to participate in this noninterventional study |
| Ausschlusskriterien | <ul style="list-style-type: none">- There are no exclusion criteria for this study |
| Alter | 18 Jahre und älter |
| Prüfzentren | Urologie (Rekrutierung beendet) Theodor-Stern-Kai 7 60590 Frankfurt am Main Dr. med. Severine Banek Tel: 069 6301-80072 Fax: 069 6301-84029 severine.banek@unimedizin-ffm.de Universitätsklinikum Frankfurt (Rekrutierung beendet) Zentrum für Chirurgie, Klinik für Urologie Theodor-Stern-Kai 7 60590 Frankfurt am Main Dr. med. Severine Banek Tel: 069 6301-80072 Fax: 069 6301-84029 severine.banek@unimedizin-ffm.de |
| Sponsor | Ipsen Pharma |
| Registrierung in anderen Studienregistern | ClinicalTrials.gov NCT03419572 (primäres Register) |